Industry feedback on the Office of Drug Control’s review of the structure, design and administration of medicinal cannabis permits is due this Friday (December 18, 2020).
The ODC’s review forms part of broader reforms being implemented as a result of the statutory Review of the Narcotic Drugs Act 1967 undertaken in 2019 by Professor John McMillan AO.
It considers ways to simplify permit arrangements and proposes implementing periodic reporting and compliance monitoring to maintain appropriate regulatory outcomes under the Medicinal Cannabis Scheme.
It aims to simplify the level of detail in the permits, particularly for cultivation and production, allow for greater flexibility in business decision-making, improve the ODC’s efficiency as well as industry understanding of regulatory obligations and compliance requirements.
To make a submission, click here.
